DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
Recruiting now
Conditions studied: Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer, Ovarian Cancer, Screening, Safety, Reduced Mortality, Reduced Morbidity, Early Diagnosis
In brief
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
Key facts
- Study ID
- NCT02288676
- Run by
- McGill University
- People needed
- 1200
- Starts
- 2014-01-01
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2025-06-18
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Royal Victoria Hospital (Glen Site) — Montreal, Quebec, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.